ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
 - EconoTimes)
NEW ORLEANS, Sept. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against PetMed Express, Inc. (NASDAQ:PETS), if they purchased the Company’s securities between May 8, 2017, and August 23, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of Florida.
Get Help
PetMed Express investors should visit us at https://www.claimsfiler.com/cases/view-petmed-express-inc-securities-litigation-1 or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
PetMed Express and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 23, 2017, it was revealed through a comprehensive report issued by Aurelius Value entitled “PetMed: Exploiting America’s Opioid Epidemic” that PetMed Express had targeted its products, painkillers especially addictive synthetic opiates, to opioid users through the aggressive use of Google ads and other online marketing services, potentially facilitating the abuse of opiates as “human crossover painkillers.”
On this news, the price of PetMed Express shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
